Eli Lilly and Company
Business & Industry
- Pfizer completes licensing agreement with 3SBio
- AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
- Vividion Therapeutics and Bayer further strengthen oncology development pipeline with clinical-stage WRN inhibitor
- ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases
- Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer
Research & Development
- New treatment could reduce brain damage from stroke, study in mice shows
- New tool helps predict antibiotic resistance
- Healthy diet can slow down chronic diseases in older people
- Patients' own autoantibodies may hold key to boosting cancer immunotherapy response
- Llama antibodies: New therapeutic avenues against schizophrenia
- Surprising finding could pave way for universal cancer vaccine
- New chemical tool may improve development of key drug components
Conferences & Events
- Cohort data from Denmark show real-world evidence of stable protection against HPV-related cervical cancer
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy